13

Gastroesophageal reflux disease (GERD) is a complex condition characterized by the backward flow of refluxate into the esophagus. Despite its prevalence and frequent clinical diagnosis, the pathogenesis of GERD is multifaceted. Many patients continue to experience persistent symptoms of GERD even after extended treatment with proton pump inhibitors (PPIs) for acid suppression. The development of GERD involves a dynamic interaction of chemical, mechanical, psychological, and neurological factors, all of which influence symptom manifestation, diagnosis, and treatment approaches. Consequently, GERD should be considered a condition that extends beyond simple acid reflux. This review will explore the key contributors to GERD pathogenesis, including aspects related to the refluxate, esophageal defense mechanisms, and factors that facilitate pathological reflux into the esophagus. Additionally, this paper will discuss recent therapeutic advancements and highlight potential future research directions in the management of GERD

  • Ўқишлар сони 13
  • Нашр санаси 05-04-2025
  • Мақола тилиIngliz
  • Саҳифалар сони14-26
English

Gastroesophageal reflux disease (GERD) is a complex condition characterized by the backward flow of refluxate into the esophagus. Despite its prevalence and frequent clinical diagnosis, the pathogenesis of GERD is multifaceted. Many patients continue to experience persistent symptoms of GERD even after extended treatment with proton pump inhibitors (PPIs) for acid suppression. The development of GERD involves a dynamic interaction of chemical, mechanical, psychological, and neurological factors, all of which influence symptom manifestation, diagnosis, and treatment approaches. Consequently, GERD should be considered a condition that extends beyond simple acid reflux. This review will explore the key contributors to GERD pathogenesis, including aspects related to the refluxate, esophageal defense mechanisms, and factors that facilitate pathological reflux into the esophagus. Additionally, this paper will discuss recent therapeutic advancements and highlight potential future research directions in the management of GERD

№ Муаллифнинг исми Лавозими Ташкилот номи
1 Nazarov N.N. Assistant lecturer Alfraganus university
№ Ҳавола номи
1 1.Vakil N, van Zanten SV, Kahrilas K, et al.2006. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol 101: 1900–1920.[DOI] [PubMed] [Google Scholar]2.Ang D, How CH & Ang TL 2016. Persistent gastrooesophagealreflux symptoms despite proton pump inhibitor therapy. Singapore Med. J 57: 546–551.[DOI] [PMC free article] [PubMed] [Google Scholar]3.Castell DO, Murray JA, Tutuian OR, et al. 2004. Review article: the pathophysiology of gastro-oesophageal reflux disease–oesophageal manifestations. Aliment. Pharmacol. Ther 20(Suppl. 9): 14–15.[DOI] [PubMed] [Google Scholar]4.Tack J & Pandolfino JE 2018. Pathophysiology of gastroesophageal reflux disease. Gastroenterology 54: 277–288.[DOI] [PubMed] [Google Scholar]5.Orlando RC, Powell DW & Carney CN 1981. Pathophysiology of acute acid injury in rabbit esophageal epithelium. J. Clin. Invest 68: 286–293.[DOI] [PMC free article] [PubMed] [Google Scholar]6.Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliot M, et al. 2002. Diversity in oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50: 451–459.[DOI] [PMC free article] [PubMed] [Google Scholar]7.Ma J, Altomare A, de la Monte S, et al. 2010. HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am. J. Physiol. Gastrointest. Liver Physiol 299: G791–G798.[DOI] [PMC free article] [PubMed] [Google Scholar]8.Isomoto H, Wang A, Mizuta Y, et al. 2003. Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am. J. Gastroenterol 98: 551–556.[DOI] [PubMed] [Google Scholar]9.Kahrilas PJ, McColl K, Fox M, et al. 2013. The acid pocket: a target for treatment in reflux disease? Am. J. Gastroenterol 108: 1058–1064.[DOI] [PubMed] [Google Scholar]10.Mitchell DR,Derakhshan MH, Robertson EV, et al. 2016. The role of the acid pocket in gastroesophageal reflux disease. J. Clin. Gastroenterol 50: 111–119.[DOI] [PubMed] [Google Scholar]11.Emerenziani S, Ribolsi M, Guarino MPL, et al. 2014. Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in non-erosive reflux disease patients. Neurogastroent. Motil 26: 108–114.[DOI] [PubMed] [Google Scholar]12.Zerbib F, Duriez A, Roman S, et al. 2008. Determinants of gastro-esophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 57: 156–160.[DOI] [PubMed] [Google Scholar]13.Lin KM, Ueda RK, Hinder RA, et al. 1991. Etiology and importance of alkaline esophageal reflux. Am. J. Surg 162: 553–557.[DOI] [PubMed] [Google Scholar]14.Stein HJ, Feussner H, Kauer W, et al. 1994. Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am. J.Surg 167: 163–168.[DOI] [PubMed] [Google Scholar]15.Kauer WK, Peters JH, DeMeester TR, et al. 1997. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 122: 874–881.[DOI] [PubMed] [Google Scholar]16.Siddiqui A, Rodriguez-Stanley R, Zubaidi S, et al. 2005. Esophageal visceral sensitivity to bile salts in patients with functional heartburn andin health control subjects. Dig. Dis. Sci 50: 81–85.[DOI] [PubMed] [Google Scholar]17.Nehra D, Howell P, Williams CP, et al. 1999. Toxic bile acids in gastroesophageal refluxdisease: influence of gastric acidity. Gut 44: 598–602.[DOI] [PMC free article] [PubMed] [Google Scholar]18.Pace F, SangalettiO, Pallotta S, et al. 2007. Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand. J. Gastroenterol 42: 1031–1039.[DOI] [PubMed] [Google Scholar]19.Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. 2009. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhitibor once daily. Am. J. Gastroenterol 104: 2005–2013.[DOI] [PubMed] [Google Scholar]20.de Bortoli N, Gyawali CP, Frazzoni M, et al. 2020. Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal base-line impedance and chemical clearance. Neurogastroenterol. Motil e13919. 10.1111/nmo.13919[DOI] [PubMed]21.Vaezi MF & Richter JE 1996. Role of acid and duo-denogastroesophagealreflux in gastroesophageal reflux disease. Gastroenterology 111: 1192–1199.[DOI] [PubMed] [Google Scholar]22.Sun D, Wang X, Gai Z, et al. 2015. Bile acids but not acidic acids induce Barrett’s esophageal. Int. J. Clin. Exp. Pathol 8: 1384–1392.[PMC free article] [PubMed] [Google Scholar]23.McQuaid KR, Laine L, Fennerty MB, et al. 2011. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment. Pharmacol. Ther 34: 146–165.[DOI] [PubMed] [Google Scholar]24.Dvorak K, Payne CM, Chavarria M, et al. 2007. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus. Gut 56: 763–771.[DOI] [PMC free article] [PubMed] [Google Scholar]25.Vaezi MF, Fass R, Vakil N, et al. 2020. IW-3718 reduces heartburn severity in patients with refractory gastroesophageal reflux disease in a randomized trial. Gastroenterology 158: 2093–2103.[DOI] [PubMed] [Google Scholar]
Кутилмоқда